SB 2447, titled the "Repealing the Trump Sick Tax Act," would undo two provisions enacted in Public Law 119-21. First, it repeals changes to Medicaid cost-sharing requirements, directing that Title XIX of the Social Security Act be applied as though those changes had never been enacted. It also rescinds any amounts appropriated under the repealed Medicaid provision.
Second, the bill repeals changes to the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program, restoring the prior treatment of orphan drugs under Title XI of the Social Security Act. In practical terms, the bill is a rollback measure: it seeks to reverse recent federal changes affecting Medicaid beneficiaries and the Medicare prescription drug negotiation framework.
Impact
If enacted, the bill would restore prior federal law governing Medicaid cost sharing and Medicare drug price negotiation, removing the effects of sections 71120 and 71203 of Public Law 119-21. That would affect Medicaid enrollees, states administering Medicaid, and pharmaceutical manufacturers—especially companies developing orphan drugs that had been affected by the negotiation program changes. The bill also rescinds related appropriated funds tied to the Medicaid provision, which would eliminate any associated federal spending authorized by the repealed section.
Sentiment
The available context suggests the bill is framed in strongly negative terms toward the prior law, as reflected in its title and short text, but there is no committee transcript or recorded vote history provided to show broader deliberation. Based on the introduction by Senators Welch and Wyden, the bill appears to have support from lawmakers seeking to reverse what they characterize as harmful health-care policy changes. Because no votes or hearing remarks are included, the overall legislative sentiment cannot be measured beyond the sponsors' clear opposition to the underlying provisions.
Contention
The main points of contention are the Medicaid cost-sharing changes and the exclusion of orphan drugs from Medicare drug price negotiation. Supporters of repeal are likely to argue that the prior changes increased costs for patients and weakened protections for vulnerable populations, while opponents would likely defend the original provisions as cost-control or budgetary measures. The orphan-drug provision is especially likely to be contested because it pits drug-pricing reform against incentives for rare-disease drug development, and the Medicaid repeal raises broader disputes over beneficiary cost sharing, state program administration, and federal spending.